azacitidine has been researched along with Leukemia, Lymphoblastic, Acute, T Cell in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (14.29) | 29.6817 |
| 2010's | 8 (57.14) | 24.3611 |
| 2020's | 4 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, W; Lin, C; Lin, D; Lin, L; Xie, Y | 1 |
| Angelopoulou, MK; Chatzidimitriou, C; Konstantopoulos, K; Korkolopoulou, P; Lafioniatis, S; Lakiotaki, E; Pappa, V; Plata, E; Vassilakopoulos, TP | 1 |
| Liu, SB; Qiao, M; Qiu, QC; Shen, XD; Wan, CL; Xue, SL; Yin, J; Zou, JY | 1 |
| Bensberg, M; Benson, M; Gustafsson, M; Lagerwall, C; Lentini, A; Nestor, CE; Rundquist, O; Selimović, A; Vogt, H | 1 |
| Binder, E; El Chaer, F; Emadi, A; Holtzman, N; Koka, M; Porter, NC; Rapoport, AP; Singh, ZN | 1 |
| Boumber, Y; Fang, Z; Garcia-Manero, G; Gonzalez-Cervantes, EA; Kuang, SQ; Wei, Y; Yang, H; Zweidler-McKay, PA | 1 |
| Hochhaus, A; Kunert, C; Schnetzke, U; Scholl, S; Schrenk, K; Spies-Weisshart, B | 1 |
| Cheng, H; Hu, X; Huang, C; Liu, J; Tang, G; Wang, J; Yang, J; Zhou, H | 1 |
| Bhatla, T; Burke, MJ; Carroll, WL; Lu, BY; Thanawala, SU; Zochowski, KC | 1 |
| Astolfi, A; Bertuccio, SN; Melchionda, F; Pession, A; Serravalle, S | 1 |
| Barwe, SP; Gopalakrishnapillai, A; Quagliano, A | 1 |
| Baldus, CD; Bohne, A; Heesch, S; Hofmann, WK; Mossner, M; Schlee, C; Thibaut, J; Thiel, E | 1 |
| Assaraf, YG; Bram, EE; Raz, S; Stark, M | 1 |
| Ardekani, AM; Jeddi Tehrani, M; Soleymani Fard, S | 1 |
14 other study(ies) available for azacitidine and Leukemia, Lymphoblastic, Acute, T Cell
| Article | Year |
|---|---|
5-Aza-dC promotes T-cell acute lymphoblastic leukemia cell invasion via downregulation of DNMT1 and upregulation of MMP-2 and MMP-9.
Topics: Animals; Azacitidine; Cell Line, Tumor; Decitabine; DNA; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Down-Regulation; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; T-Lymphocytes; Up-Regulation | 2022 |
Pancytopenia, eosinophilia and coagulation disorders in a patient with T-acute lymphoblastic leukemia in prolonged remission.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Biomarkers, Tumor; Blood Cell Count; Bone Marrow; Cancer Survivors; Chromosome Deletion; Chromosome Disorders; Chromosomes, Human, Pair 7; Diagnosis, Differential; Eosinophilia; Hemorrhagic Disorders; Humans; Interferon-alpha; Leukemia, Myeloid, Acute; Male; Mastocytosis, Systemic; Myelodysplastic Syndromes; Neoplasms, Second Primary; Pancytopenia; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Staurosporine; Tryptases | 2021 |
Venetoclax combined with azacitidine as an effective and safe salvage regimen for relapsed or refractory T-cell acute lymphoblastic leukemia: a case series.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Salvage Therapy; Sulfonamides; T-Lymphocytes | 2021 |
TET2 as a tumor suppressor and therapeutic target in T-cell acute lymphoblastic leukemia.
Topics: Antimetabolites, Antineoplastic; Antioxidants; Apoptosis; Ascorbic Acid; Azacitidine; Biomarkers, Tumor; Cell Proliferation; Dioxygenases; DNA Methylation; DNA-Binding Proteins; Drug Therapy, Combination; Gene Expression Regulation, Neoplastic; Humans; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Promoter Regions, Genetic; RNA-Seq; Tumor Cells, Cultured | 2021 |
Durable remission with salvage decitabine and donor lymphocyte infusion (DLI) for relapsed early T-cell precursor ALL.
Topics: Aged; Azacitidine; Decitabine; Humans; Lymphocyte Transfusion; Male; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Salvage Therapy; Treatment Outcome | 2017 |
Epigenetic inactivation of Notch-Hes pathway in human B-cell acute lymphoblastic leukemia.
Topics: Apoptosis; Azacitidine; B-Lymphocytes; Basic Helix-Loop-Helix Transcription Factors; Blood Cells; Bone Marrow; Calcium-Binding Proteins; Cell Line, Tumor; Cell Lineage; Cell Proliferation; Decitabine; DNA Methylation; Epigenesis, Genetic; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Gene Silencing; Hematopoiesis; Histones; Humans; Hydroxamic Acids; Intercellular Signaling Peptides and Proteins; Jagged-1 Protein; Leukemia, B-Cell; Membrane Proteins; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Receptor, Notch3; Receptors, Notch; Repressor Proteins; Serrate-Jagged Proteins; Signal Transduction; T-Lymphocytes; Transcription, Genetic; Vorinostat | 2013 |
Different clones of acute leukemia after successful treatment of Hodgkin's disease.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Azacitidine; Bleomycin; Bone Marrow; Clone Cells; Consolidation Chemotherapy; Dacarbazine; Doxorubicin; Fatal Outcome; Female; fms-Like Tyrosine Kinase 3; Hodgkin Disease; Humans; Immunophenotyping; Leukemia, Myelomonocytic, Acute; Neoplasm Proteins; Neoplasms, Second Primary; Neoplastic Stem Cells; Palliative Care; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Salvage Therapy; Vinblastine | 2014 |
[Effects of decitabine against acute T lymphoblastic leukemia cell line Molt4].
Topics: Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Caspase 3; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Decitabine; DNA Methylation; Humans; Lactoferrin; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Promoter Regions, Genetic | 2015 |
Decitabine enhances chemosensitivity of early T-cell precursor-acute lymphoblastic leukemia cell lines and patient-derived samples.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Basic Helix-Loop-Helix Transcription Factors; Cell Line, Tumor; Cell Survival; Decitabine; Drug Synergism; Gene Expression Regulation, Leukemic; Humans; Jurkat Cells; Mice; Neoplasm Proteins; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Receptors, Interleukin-7; Reverse Transcriptase Polymerase Chain Reaction; Xenograft Model Antitumor Assays | 2016 |
Synergistic Cytotoxic Effect of L-Asparaginase Combined with Decitabine as a Demethylating Agent in Pediatric T-ALL, with Specific Epigenetic Signature.
Topics: Asparagine; Aspartate-Ammonia Ligase; Azacitidine; Cell Line, Tumor; Cell Survival; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Epigenesis, Genetic; Humans; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Transcriptome | 2016 |
Epigenetic drug combination overcomes osteoblast-induced chemoprotection in pediatric acute lymphoid leukemia.
Topics: Animals; Azacitidine; Coculture Techniques; DNA Modification Methylases; Drug Resistance, Neoplasm; Epigenesis, Genetic; Heterografts; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Mice; Osteoblasts; Panobinostat; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Tumor Cells, Cultured | 2017 |
Epigenetic control of differential expression of specific ERG isoforms in acute T-lymphoblastic leukemia.
Topics: Azacitidine; Base Sequence; CpG Islands; Decitabine; DNA Methylation; DNA Primers; Epigenesis, Genetic; Exons; Oncogene Proteins; Polymerase Chain Reaction; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Protein Isoforms; Trans-Activators; Transcriptional Regulator ERG | 2009 |
Chemotherapeutic drug-induced ABCG2 promoter demethylation as a novel mechanism of acquired multidrug resistance.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Azacitidine; Cell Line, Tumor; Cell Proliferation; Cytidine; Decitabine; DNA Methylation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Jurkat Cells; K562 Cells; Neoplasm Proteins; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction | 2009 |
Prostaglandin E2 induces growth inhibition, apoptosis and differentiation in T and B cell-derived acute lymphoblastic leukemia cell lines (CCRF-CEM and Nalm-6).
Topics: Antineoplastic Agents; Apoptosis; Azacitidine; Caspase 3; Cell Cycle; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Decitabine; Dinoprostone; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Flow Cytometry; Humans; Hydroxamic Acids; Inhibitory Concentration 50; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 2012 |